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SUMMARY
Objective: Themulticenter National Infantile Spasms Consortium prospective cohort
was used to compare outcomes and phenotypic features of patients with infantile
spasmswith andwithout hypsarrhythmia.
Methods: Patients aged 2 months to 2 years were enrolled prospectively with new-
onset infantile spasms. Treatment choice and categorization of hypsarrhythmia were
determined clinically at each site. Response to therapy was defined as resolution of
clinical spasms (and hypsarrhythmia if present) without relapse 3 months after initia-
tion.
Results: Eighty-two percent of patients had hypsarrhythmia, but this was not associ-
ated with gender, mean age, preexisting developmental delay or epilepsy, etiology, or
response to first-line therapy. Infants with hypsarrhythmia weremore likely to receive
standard treatment (adrenocorticotropic hormone, prednisolone, or vigabatrin [odds
ratio (OR) 2.6, 95% confidence interval (CI) 1.4–4.7] and preexisting epilepsy reduced
the likelihood of standard treatment (OR 3.2, 95% CI 1.9–5.4). Hypsarrhythmia was
not a determinant of response to treatment. A logistic regression model demon-
strated that later age of onset (OR 1.09 per month, 95% CI 1.03–1.15) and absence of
preexisting epilepsy (OR 1.7, 95% CI 1.06–2.81) had a small impact on the likelihood of
responding to the first-line treatment. However, receiving standard first-line treat-
ment increased the likelihood of responding dramatically: vigabatrin (OR 5.2 ,95% CI
2–13.7), prednisolone (OR 8, 95% CI 3.1–20.6), and adrenocorticotropic hormone
(ACTH;OR 10.2, 95%CI 4.1–25.8) .
Significance: First-line treatmentwith standard therapywas by far themost important
variable in determining likelihood of response to treatment of infantile spasms with or
without hypsarrhythmia.
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West syndrome (WS) is an electroclinical syndrome con-
sisting of epileptic spasms (a seizure type characterized by
sudden flexion or extension predominantly of proximal
muscles1) and hypsarrhythmia2 on electroencephalography
(EEG), and is typically associated with existing or evolving
developmental delay.3–5 WS has an incidence of 2–4.5 per
10,000 live births6–10 and is associated with numerous
etiologies. Infantile spasms is a broader term that can
encompass any patient with onset of epileptic spasms during
infancy, approximately 75% of whom have hypsarrhythmia
at the time of diagnosis.9,11
Hypsarrhythmia is the EEG findings of random or chaotic
high-amplitude slow waves with intermixed multifocal
spikes.5 Controversy exists regarding the specific
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amplitudes (>200 lV or >300 lV) required and the fre-
quency and distribution of spikes.5,11–15 This variability
likely accounts, at least in part, for poor interrater reliability
when classifying hypsarrhythmia.16 Nevertheless, this con-
tinues to be considered an important clinical biomarker of a
poor prognosis.13,15,17–20 Even greater controversy exists
regarding specific definitions and utility of modified hyp-
sarrhythmia patterns.15,19 Separating hypsarrhythmia from
the associated epileptic spasms and the underlying pathol-
ogy has been challenging. Cohort studies of patients with
infantile spasms without hypsarrhythmia suggest that they
have varied outcomes and respond to treatments similar to
those with hypsarrhythmia.21–24 However, patients with and
without hypsarrhythmia have never been compared system-
atically within the same data set.
In 2012 the multicenter Pediatric Epilepsy Research Con-
sortium created the National Infantile Spasms Consortium
(NISC) database, which has allowed for a systematic,
prospective evaluation of response to various first- and sec-
ond-line therapies14,25 The NISC enrolled patients with
infantile spasms with and without hypsarrhythmia, making
it a useful database to determine the effect of hypsarrhyth-
mia on response to treatment. In this study, we used the
NISC database to evaluate a cohort of patients with infantile
spasms without hypsarrhythmia and compare them to those
with hypsarrhythmia in terms of phenotypic features and
outcomes. The primary aim was to determine (1) whether
patients without hypsarrhythmia should be treated with
medication different from those with hypsarrhythmia and
(2) if they have a different likelihood of responding to their
first-line treatment. In addition, we evaluated the associa-
tion between hypsarrhythmia and the following phenotypic
features: age (particularly <3 months at onset of infantile
spasms22), development, preexisting epilepsy, sex, time
interval from onset to diagnosis, and underlying etiology.
Finally, we assessed the influence of hypsarrhythmia on
treatment choice.
Methods
After written informed consent was obtained from par-
ents or guardians, the patients, who were between 2 months
and 2 years with new-onset infantile spasms (defined by the
occurrence of epileptic spasms) were enrolled in the NISC
multicenter database prospectively as described previ-
ously.14,25,26 Patients with early infantile epileptic
encephalopathy (Ohtahara syndrome) or early myoclonic
epilepsy were excluded from the study. Also excluded were
patients with incomplete data.
Sex, age at spasm onset, diagnosis, treatment initiation,
developmental status prior to spasm onset, prior use of any
antiseizure drug (ASD), use of ASDs at the time of diagno-
sis, and etiology was noted for each patient. Etiology was
grouped into seven main categories: genetic/ metabolic,
neonatal, neurocutaneous, stroke, structural, and unknown
cause with either normal development or abnormal develop-
ment prior to onset of infantile spasms. Development was
determined by treating physicians and was grouped into nor-
mal or near normal and clearly abnormal.14
There was no specific variable for preexisting epilepsy.
Therefore, as a surrogate we utilized whether a patient was
already taking an ASD at the time they were diagnosed with
infantile spasms. It would be unlikely that infants with clear
epilepsy prior to the onset of infantile spasms would have
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Key Points
• Hypsarrhythmia is not predictive of response to first-
line therapy
• Early age at onset of infantile spasms and a history of
preexisting epilepsy slightly reduce the likelihood of
responding to first-line treatment
• Use of standard first-line medications (ACTH, vigaba-
trin, prednisolone) have by far the largest impact on
the odds of response to first-line treatment
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been weaned from treatment prior to the onset of infantile
spasms. This variable is referred to as preexisting epilepsy
for convenience throughout the results.
Hypsarrhythmia was defined as random or chaotic high-
voltage (>200 lV) slow waves with intermixed multifocal
spikes and was determined by the referring epileptologist at
each site. Modified hypsarrhythmia was noted in the data-
base but there was no clear definition provided for modified
hypsarrhythmia. Modified hypsarrhythmia and hypsar-
rhythmia were grouped for the purposes of this study given
the poor interrater reliability in determining hypsarrhythmia
and modified hypsarrhythmia.16 Hypsarrhythmia has been
defined broadly in this database.5
Physicians at each site determined the therapy for each
patient based on their own clinical judgment, but standard
dosing recommendations were made for adrenocorti-
cotropic hormone (ACTH), oral corticosteroids (pred-
nisolone), and vigabatrin, as described preciously.14 These
treatments were defined as standard therapies for treatment
of infantile spasms. All other treatments were considered
nonstandard treatments. Nonstandard treatment includes
nine different treatments, with the three most common being
levetiracetam, topiramate, and clobazam. Response to ther-
apy was defined as resolution of clinical epileptic spasms
and resolution of hypsarrhythmia (if present) within
2 weeks of initiating therapy, without relapse at 3 months
after initiation. Patients who had an incomplete response, no
response, or relapse were considered nonresponders.14
None of the patients enrolled to NISC during this period
received combinatorial therapy with more than one standard
therapy.
All parents provided written informed consent according
to center-specific institutional review boards (IRBs), and
the study was approved by the IRBs of all participating insti-
tutions. Data used in this study were collected between June
2012 and November 2016.
Statistical analysis
The associations between hypsarrhythmia at onset of
infantile spasms and categorical variables such as sex, pre-
existing epilepsy, preexisting developmental delay, etiol-
ogy, and age at onset (<3 months vs. ≥3 months) were
assessed using chi-square analysis. Student’s t-test was used
to compare age at onset and time from onset to treatment
between the two groups. Response to standard versus non-
standard therapy was assessed independently in those with
and without hypsarrhythmia. In addition, a multivariable
logistic regression model evaluated the impact of age at
onset, preexisting epilepsy, prior development, etiology,
and the presence of hypsarrhythmia on first-line treatment
choice. Finally, the association between response and first-
line treatment was assessed through a multivariable logistic
regression model that adjusted for factors that were found to
be potential determinants of treatment choice or potentially
predictive of response to therapy including the presence of
hypsarrhythmia, age at onset of epilepsy, preexisting epi-
lepsy, and choice of drug (ACTH, prednisolone, vigabatrin,
or others). The predictors were evaluated for potential
collinearity and important interactions. All statistical analy-
sis was performed using SAS version 9.4, and statistical sig-
nificance was defined as p < 0.05.
Results
A total of 447 patients were enrolled with infantile
spasms; 366 (82%) with hypsarrhythmia and 81 (18%) with-
out hypsarrhythmia. All patients without hypsarrhythmia
had abnormal EEG backgrounds. Sex, age at onset, time
from onset of spasms to diagnosis, presence of moderate or
severe preexisting developmental delay, preexisting epi-
lepsy, and etiology were not different in the two groups
(Table 1). Although mean age at onset of infantile spasms
was the same in the two groups, infants <3 months of age at
onset of infantile spasms were less likely to have hypsar-
rhythmia (18 of 30, 60.0%) compared to those ≥3 months
(348 of 417, 83.5%; p = 0.001).
Chi-square and multivariable logistic regression model-
ing determined that only hypsarrhythmia and preexisting
epilepsy were significantly related to prescription of a stan-
dard medication as first-line therapy. Infants with hypsar-
rhythmia were 2.6 times more likely (95% confidence
interval [CI] 1.4–4.7) to be prescribed standard therapy
compared with infants who did not have hypsarrhythmia.
Patients without preexisting epilepsy were 3.2 times more
likely (95% CI 1.9–5.4) to receive standard first-line ther-
apy compared to patients with previously diagnosed epi-
lepsy (Table 2).
Response to treatment was equivalent in those with and
without hypsarrhythmia (Table 1), despite the observation
that patients without hypsarrhythmia were less likely to be
prescribed standard therapy (72% vs. 87%, p < 0.0004).
Prescription of standard therapy was independently associ-
ated with an increased likelihood of responding to the first
therapy, both among patients with hypsarrhythmia
(p < 0.0001) and without hypsarrhythmia (p < 0.0001). Of
the 81 patients without hypsarrhythmia, 58 patients received
one of the standard therapies and 27 patients (47%)
responded. None of the 23 patients without hypsarrhythmia
who were prescribed nonstandard therapy responded
(p < 0.0001).
Age at onset of infantile spasms and preexisting epilepsy
were associated with response to therapy on univariate anal-
ysis (p = 0.01 and p = 0.0007, respectively). In the multi-
variable logistic regression, odds of response to therapy
increased 1.09 (95% CI 1.03–1.15) times for each month
increase in age at onset of infantile spasms (p = 0.002),
after adjusting for relevant clinical factors. There was no
statistically significant interaction between hypsarrhythmia
and age at onset within this model. Patients without a diag-
nosis of epilepsy at the onset of infantile spasms were 1.7
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(95% CI 1.06–2.81) times more likely to respond to therapy
(p = 0.027, Table 3).
The presence of hypsarrhythmia did not impact likeli-
hood of treatment response (p = 0.8). Compared to nonstan-
dard treatments, first-line treatment with ACTH,
prednisolone, and vigabatrin increased the odds of response
by 10.2 (95% CI 4.1–25.8, p < 0.001), 8 (95% CI 3.1–20.6,
p < 0.001), and 5.2 (95% CI: 2–13.7, p = 0.0009) times,
respectively (Table 3).
Discussion
The results of this study suggest that patients with infan-
tile spasms with or without hypsarrhythmia benefit from the
same treatment strategy using one of the first-line medica-
tions (ACTH, prednisolone, or vigabatrin). None of the
patients without hypsarrhythmia who received nonstandard
therapy responded. A prescribing bias was also identified,
as patients without hypsarrhythmia or with a history of pre-
existing epilepsy were less likely to receive standard first-
line medications.
The youngest patients (<3 months) were less likely to
have hypsarrhythmia at presentation, but patients without
hypsarrhythmia were seen at all ages (2 months to 2 years).
A similar overrepresentation of patients <3 months was
reported previously in a cohort of patients with infantile
spasms without hypsarrhythmia, where 3 of 16 (19%) were
<3 months of age at onset.22 In our data, there were no other
factors that correlated with absence of hypsarrhythmia.
Specifically, there was no difference in the time from onset
of infantile spasms to diagnosis of infantile spasms based on
hypsarrhythmia. This argues against the theory that patients
without hypsarrhythmia have been captured earlier and
would develop hypsarrhythmia eventually if left untreated.
However, a detailed analysis of subsequent EEG studies
was beyond the scope of this study. Similarly, there was no
Table 1. Comparison of characteristics based on the presence of hypsarrhythmia
Characteristic
Hypsarrhythmia
N (%) or mean (SD)
No hypsarrhythmia
N (%) or mean (SD) p-Value
Overall 366 (82) 81 (18)
Female 167 (46) 35 (43) 0.69
Preexisting epilepsy 104 (29) 30 (38) 0.13
Moderate or severe developmental delay 218 (60) 47 (59) 0.85
Average age at onset (months) 7.2 (4) 6.9 (4.7) 0.56
Time from onset of spasms to diagnosis (months) 0.97 (1.9) 0.75 (1.1) 0.17
Onset of spasms at <3 months age 18 (5) 12 (15) 0.0013
Etiology 0.06
Genetic/metabolic 68 (20) 12 (15)
Neonatal 49 (14) 14 (18)
Neurocutaneous 18 (5) 10 (13)
Stroke 19 (6) 4 (5)
Structural 44 (13) 16 (20)
Unknown abnormal development 78 (23) 13 (16)
Unknown normal development 68 (20) 10 (13)
First-line treatment prescribed
Standard 320 (87) 58 (72) 0.0004a
Other treatments 46 (13) 23 (28)
ACTH 196 (46) 20 (25) 0.0002b
Prednisolone 85 (23) 18 (22)
Vigabatrin 66 (18) 20 (25)
Other treatments 46 (13) 23 (28)
Response to treatment
Overall
Responders 148 (40) 27 (33) 0.24
Nonresponders 218 (60) 54 (67)
Standard treatment
Responder 142 (44) 27 (47) 0.76
Nonresponder 178 (56) 31 (53)
Other treatments
Responders 6 (13) 0 (0) 0.17
Nonresponders 40 (87) 23 (100)
Characteristics of patients with and without hypsarrhythmia at the time of diagnosis. Number of patients within the group (hypsarrhythmia or not hypsarrhyth-
mia) that had that characteristic followed by the percentage in parenthesis. Bold values indicate statistically significant p-values.
aChi-square test comparing prescribing of standard versus other for first-line treatment.
bChi-square test comparing prescribing of ACTH, prednisolone, vigabatrin, and other for first-line treatment.
Epilepsia, 58(12):2098–2103, 2017
doi: 10.1111/epi.13937
2101
Impact of Hypsarrhythmia on Treatment
difference in the gross assessment of development of infants
at the time of diagnosis of infantile spasms between the two
groups.
Etiology was not associated with the presence or absence
of hypsarrhythmia. Etiology is possibly the most difficult
factor to analyze in studying infantile spasms because there
are likely more than 100 unique causes.26,27 To analyze data
sets based on each individual diagnosis reduces statistical
power to the point of being impractical. We grouped
patients into seven categories, which cannot capture
detailed phenotypic information that may be inherent to a
specific etiology. With this caveat in mind the grouping we
utilized was not associated with the presence of hypsar-
rhythmia. The impact of specific etiologies on phenotype
and outcomes deserves additional exploration, and the use
of large multicenter databases, like NISC, will prove invalu-
able in this effort as the number of enrolled patients contin-
ues to grow.
Ultimately, this study reaffirms that the primary predictor
of response to therapy is the use of standard therapy (ACTH,
prednisolone, or vigabatrin). Although these treatments
were not randomized, they were standardized, and as
reported previously, most patients did receive the recom-
mended dose and duration.14 NISC is the largest prospective
study to date for infantile spasms and clearly demonstrates
that earlier age at onset and preexisting epilepsy negatively
impact the likelihood of response to therapy, but this impact
is modest when compared to treatment choice. After adjust-
ment for treatment bias, hypsarrhythmia is not associated
with response to treatment.
The NISC database is limited as a prospective observa-
tional study without randomization or long-term follow-
up.14,25 Although a randomized controlled trial is ideal for
determining the optimal treatment, and adjusting for unmea-
sured confounders, the NISC database allows for adjustment
of many confounders and identification of clinical prescrib-
ing biases. Additional study is warranted into the long-term
implications of hypsarrhythmia on neurodevelopment.
However, most evidence available now suggests that each
patient has his or her own range of potential outcomes,
heavily influenced by their underlying etiology, and that
rapid and effective treatment of infantile spasms likely
improves a given patient’s trajectory within that contin-
uum.28–32 Data on long-term developmental outcomes
would be a valuable avenue for future research. We supple-
ment use of an ASD at the time of infantile spasms diagnosis
for preexisting epilepsy; while these are likely heavily cor-
related parameters the significance of “preexisting epilepsy”
in this paper should be verified with additional studies.
Finally, poor interrater reliability between EEG readers
when evaluating for hypsarrhythmia remains a potential lim-
itation.16 However, as hypsarrhythmia was classified clini-
cally in our multicenter study, our approach and our data are
representative of current clinical practice. Therefore, this
study suggests that use of hypsarrhythmia as a clinically
meaningful predictor of response to therapy for epileptic
spasms in children <2 years of age is inappropriate.
This analysis demonstrates that patients who receive
ACTH, prednisolone, or vigabatrin as first-line treatment
have 5–10 times the odds of responding to their initial medi-
cation, compared to children who are prescribed nonstan-
dard treatments. Although early age at onset and preexisting
epilepsy had some impact on response, first-line treatment
with standard therapy was by far the most important
Table 2. Factors impacting the odds of receiving standard therapy
Variable Odds ratio
95% Wald
p-Valueconfidence limits
Presence of hypsarrhythmia 2.6 1.4 4.7 0.0015
Preexisting epilepsy 3.2 1.9 5.4 <0.0001
Multivariable logistic regression model evaluating the association between the variables and likelihood of being prescribed a standard therapy as first-line ther-
apy. Odds ratio with associated confidence intervals and p-values are provided.
Table 3. Factors impacting the odds of response to first-line treatment
Variable Odds ratio
95% Wald
p-Valueconfidence limits
Presence of hypsarrhythmia 0.949 0.54 1.669 0.8556
Age at onset of infantile spasms 1.088 1.032 1.148 0.0018
Preexisting epilepsy 1.728 1.063 2.809 0.0274
ACTH (adrenocorticotropic hormone) vs. nonstandard therapy 10.247 4.078 25.751 <0.0001
PRL (prednisolone) vs. nonstandard therapy 7.981 3.092 20.601 <0.0001
VGB (vigabatrin) vs. nonstandard therapy 5.171 1.953 13.688 0.0009
Multivariable logistic regression model evaluating the association between the variables and likelihood of response to first-line therapy. Odds ratio with associ-
ated confidence intervals and p-values are provided.
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variable in determining likelihood of response to treatment
of infantile spasms regardless of the presence or absence of
hypsarrhythmia at the time of diagnosis.
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